bioAffinity Technologies, Inc. (BIAFW) Financial Statements (2026 and earlier)

Company Profile

Business Address 3300 NACOGDOCHES ROAD
SAN ANTONIO, TX 78217
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 8731 - Commercial Physical and Biological Research (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,1052,82211,414
Cash and cash equivalent1,1052,82211,414
Inventory, net of allowances, customer advances and progress billings28186
Inventory28186
Prepaid expense396297460
Other undisclosed current assets1,16783683
Total current assets:2,6953,97311,962
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization7811,166 
Operating lease, right-of-use asset463370 
Property, plant and equipment375459214
Intangible assets, net (including goodwill)2,1802,238 
Goodwill1,4041,404 
Intangible assets, net (excluding goodwill)775833 
Other noncurrent assets20166
Total noncurrent assets:3,8194,249220
TOTAL ASSETS:6,5148,22212,182
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,3861,755887
Accounts payable987605345
Accrued liabilities1,3991,150542
Deferred revenue2433 
Debt567365252
Other undisclosed current liabilities12795 
Total current liabilities:3,1052,2481,139
Noncurrent Liabilities
Long-term debt and lease obligation465835 
Long-term debt, excluding current maturities20  
Finance lease, liability444835 
Liabilities, other than long-term debt342283 
Operating lease, liability342283 
Other undisclosed noncurrent liabilities   
Total noncurrent liabilities:8071,118 
Total liabilities:3,9123,3661,139
Equity
Equity, attributable to parent2,6024,85511,043
Common stock1076659
Additional paid in capital56,14049,39447,652
Accumulated deficit(53,644)(44,604)(36,667)
Total equity:2,6024,85511,043
TOTAL LIABILITIES AND EQUITY:6,5148,22212,182

Income Statement (P&L) ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
Revenues9,3627,9005
Cost of revenue   (0)
Gross profit:9,3627,9004
Operating expenses(18,315)(10,506)(4,015)
Other undisclosed operating loss  (5,368) 
Operating loss:(8,953)(7,973)(4,011)
Nonoperating income (expense)189447
Investment income, nonoperating1812247
Other nonoperating income (expense)0(28) 
Interest and debt expense(92)(37)(2,100)
Loss from continuing operations before equity method investments, income taxes:(9,028)(7,916)(6,064)
Other undisclosed loss from continuing operations before income taxes  (2,087)
Loss from continuing operations before income taxes:(9,028)(7,916)(8,152)
Income tax expense(12)(21)(2)
Loss from continuing operations:(9,040)(7,937)(8,154)
Other undisclosed net income  16,537 
Net income (loss):(9,040)8,600(8,154)
Other undisclosed net loss attributable to parent  (16,537) 
Net loss available to common stockholders, diluted:(9,040)(7,937)(8,154)

Comprehensive Income ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
Net income (loss):(9,040)8,600(8,154)
Comprehensive income (loss), net of tax, attributable to parent:(9,040)8,600(8,154)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: